BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) — SomaLogic (NASDAQ: SLGC), a pacesetter in AI data-driven proteomics know-how, at present introduced the appointment of present board member and biotech veteran Troy Cox as Executive Chair to the firm’s Board of Directors. The present Chair, Chuck Lillis, will stay on the board. Changes are efficient as of at present, October 17, 2022.
Mr. Cox brings over thirty years of expertise in the life sciences and biopharmaceuticals trade to his expanded place as Executive Chair of the Board. Mr. Cox was the President and CEO of Foundation Medicine from early 2017 via the acquisition by Roche, valuing Foundation Medicine at $5.3 billion. Prior to Foundation Medicine, he served as Senior Vice President and Officer at Genentech, main U.S. BioOncology for a interval of unprecedented development to over $12 billion whereas serving to to steer the Roche Genentech R&D portfolio. Before Genentech, he held government and senior roles of growing accountability together with President of UCB BioPharmaceuticals, Senior Vice President of Sanofi-Aventis, and various foundational roles at Schering-Plough.
“We thank Mr. Lillis for serving as Chair for nearly 3 years and are grateful for his continued service as a board member. We are very pleased to appoint Mr. Cox as Executive Chair of SomaLogic’s Board of Directors,” stated SomaLogic Chief Executive Officer Roy Smythe, M.D. “His input and guidance have been instrumental to our strategic and commercial progress through our 2021 Nasdaq listing and evolution as a public company. We look forward to leveraging his extensive leadership experience as we execute the next phase of SomaLogic’s growth.”
“I’m convinced that proteomics will become increasingly critical to the development of novel therapeutics and improving patient care. Somalogic is well positioned to lead the way,” stated Cox. “I am inspired by this company’s future prospects and look forward to continuing my work with such a dedicated team as Executive Chair of the Board.”
About SomaLogic
SomaLogic (Nasdaq: SLGC) seeks to ship exact, significant and actionable health-management data that empowers people worldwide to repeatedly optimize their private well being and wellness all through their lives. This important data, to be offered via a world community of companions and customers, is derived from SomaLogic’s personalised measurement of essential adjustments in a person’s proteins over time. For extra data, go to www.somalogic.com and observe @somalogic on Twitter.
Media Contact
Emilia Costales
720-798-5054
[email protected]
Investor Contacts
Lauren Glaser
[email protected]
Marissa Bych
Gilmartin Group LLC
[email protected]
